Amgen Inc. struck a research and development deal for the development of Advaxis Inc.’s pre-clinical immunotherapy treatment, ADXS-NEO.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
It’s not hard to see how precision medicine will re-make the world of research and development and manufacturing and distribution for pharmaceutical and medical product companies. But it will make new demands on the supply chains of these organizations.
Telesta Therapeutics will terminate its bladder cancer drug MCNA project, shutter its Montreal-based manufacturing facility and terminate another 30 percent of its workforce.
Takeda will refocus R&D on three targeted therapeutic areas – oncology, gastroenterology and CNS. Vaccines will also continue to play an important role.
Along with its dismal half-year financial reports, UK-based AstraZeneca announced it was halting six pipeline programs.
TauRx Pharmaceuticals’ experimental Alzheimer’s drug LMTX failed to improve cognitive and functional skills in patients with mild to moderate Alzheimer’s disease.
International Business Machines Corp. said it would provide its technology and resources to help track the spread of the Zika virus.
Boehringer Ingelheim was forced to halt two Phase III trials for lung cancer drug Gilotrif following the advice of a data monitoring committee, Pharma Times reported.
GenVec was notified by its collaborator Novartis that FDA has lifted the clinical hold on the Phase 1/2 clinical trial of CGF166 in patients with severe to profound hearing loss.
An off-patent malaria drug could help to destroy cancer cells by making them more susceptible to radiotherapy, according to early research.
Gazyva combined with chemotherapy failed to meet its primary endpoints in a Phase III trial for patients with previously untreated diffuse large B-cell lymphoma.
AstraZeneca Plc said its experimental lung cancer drug Tagrisso met its main goal in a late-stage study.
Boston’s Ziopharm Oncology released information that a patient receiving gene therapy into a brain tumor died from an intracranial hemorrhage.
The Zika outbreak rampaging through Latin America will likely burn itself out in the next two to three years, based on the fact that people develop immunity to the virus after an initial infection, British scientists said.
Being overweight or obese is linked to a higher risk of dying prematurely than being normal weight and the risk rises sharply as the extra pounds pile on, scientists said.
Sage Therapeutics Inc. said its lead drug alleviated symptoms of severe postpartum depression, meeting the main goal of a small mid-stage study.
Merck is globally committed to an antimicrobial stewardship encompassing surveillance, R&D, and health policy.
A study examining genes of more than 120,000 people from Europe, Asia, Africa and the Americas has offered the clearest picture yet of those that drive type 2 diabetes.
French biotech firm Valneva said it has produced a possible vaccine against the mosquito-borne Zika virus.
Ablynx’s hopes for a potential multibillion-dollar drug were boosted by strong clinical trial results in rheumatoid arthritis.
French drugmaker Sanofi struck an R&D deal with the U.S. Army to speed up the development of a vaccine against the mosquito-borne Zika virus.